Oral bisphosphonates for paediatric osteogenesis imperfecta?

  title={Oral bisphosphonates for paediatric osteogenesis imperfecta?},
  author={Leanne M. Ward and Frank Rauch},
  journal={The Lancet},
www.thelancet.com Published online August 6, 2013 http://dx.doi.org/10.1016/S0140-6736(13)61531-7 1 Children and adolescents with osteogenesis imperfecta have numerous fractures, often after what would otherwise seem trivial trauma. Even in mild disease, the risk of breaking a long bone (femur, tibia, fi bula, humerus, radius, or ulna) is about 100 times higher than in the general population. Almost three-quarters of young people with mild osteogenesis imperfecta have at least one fracture of a… Expand
Atypical Femoral Fractures : Three Cases And A Review Of Literature
Although antiresorptive therapy offers a very significant benefit in the prevention of osteoporotic fractures, clinicians should be aware of the possible complications, especially with long-term therapy. Expand
Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
Although it did not change the properties of the OI bone matrix material, Scl-Ab reduced the fracture rate of the long bones by improving its bone mass, density, geometry, and biomechanical strength. Expand
Bone Health and Osteoporosis Management of the Patient With Duchenne Muscular Dystrophy
This article provides a comprehensive review of the following 4 phases of bone health management: bone health monitoring, which is used to identify early signs of compromised bone health; osteoporosis stabilization,which is aimed to mitigate back pain and interrupt the fracture–refracture cycle through bone-targeted therapy; bone health maintenance, which has the goal to preserve the clinical gains realized during the stabilization phase through ongoing bone- targeting therapy. Expand
Glucocorticoid-Induced Osteoporosis: Why Kids Are Different
  • L. Ward
  • Medicine
  • Frontiers in Endocrinology
  • 2020
This study unveiled numerous key clinical-biological principles about GC-induced osteoporosis (GIO), many of which are unique to the growing skeleton, as well as recognizing that children with poor growth, older children with less residual growth potential, and children with ongoing bone health threats have less potential for vertebral body reshaping following spine fractures. Expand
The management of osteoporosis in children
The evidence that shapes the current approach to diagnosis, monitoring, and treatment of osteoporosis in childhood is reviewed, with emphasis on the key pediatric-specific biological principles that are pivotal to the overall approach and on the main questions with which clinicians struggle on a daily basis. Expand
Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect with zoledronic acid.
A RANKL-blocking antibody induced a transient arrest in long bone and skull bone growth and a blockage of tooth eruption in C57BL/6J mice and a synergic effect of both bone resorption inhibitors was evidenced. Expand
Vibration therapy: clinical applications in bone
Vibration therapy may be useful as a primary treatment as well as an adjunct to both physical and pharmacological treatments, but future studies must pay close attention to compliance and dosing patterns, and importantly, the vibration signal. Expand
Osteoporosis: Diagnosis and Management
Bone health is now recognized as an important facet of child health with sufficient evidence to support standardized approaches to diagnosis, monitoring, treatment, and prevention. Current managementExpand
Bone resorption: an actor of dental and periodontal development?
The hypothesis of a role of bone resorption in dental and periodontal development is supported by the data collected in the last years that support the presence of signals originating bone cells toward dental cells. Expand


Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
In children with severe osteogenesis imperfecta, cyclic administration of intravenous pamidronate improved clinical outcomes, reduced bone resorption, and increased bone density. Expand
Impact of Alendronate on Quality of Life in Children With Osteogenesis Imperfecta
Daily alendronate therapy is safe and effective in improving QOL in children with OI and vertebral bone mineral density improved after 1 year of alendronsate therapy. Expand
The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
The results suggest that, in the growing skeleton, pamidronate has a twofold effect: resorption is selectively targeted, and continuing bone formation can increase cortical width. Expand
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Oral ALN for 2 yr in pediatric patients with OI significantly decreased bone turnover and increased spine areal BMD but was not associated with improved fracture outcomes. Expand
Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1
Systematic follow‐up of growing patients with OI patients with COL1A1 haploinsufficiency mutations including radiographic screening for vertebral compression fractures and scoliosis is warranted, as reflected in the spine deformity index. Expand
Current and emerging treatments for the management of osteogenesis imperfecta
Suggestions and guidelines for a therapeutic approach are indicated and updated with the most recent findings in OI diagnosis and treatment. Expand
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial
Oral risedronate increased areal BMD and reduced the risk of first and recurrent clinical fractures in children with osteogenesis imperfecta, and the drug was generally well tolerated. Expand
Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study
Oral treatment with olpadronate at a daily dose of 10 mg/m2 results in a reduction of fracture risk of long bones in children with osteogenesis imperfecta, and the issue of whether bisphosphonates will alter the natural course of osteogenesisperfecta remains unresolved, and further studies are needed. Expand
The Effect of Intravenous Pamidronate on Bone Mineral Density, Bone Histomorphometry, and Parameters of Bone Turnover in Adults with Type IA Osteogenesis Imperfecta
It is indicated that intravenous pamidronate, 30 mg every 3 months, may have significant effects on bone density and histomorphometry in adults with type IA OI. Expand
New perspectives on osteogenesis imperfecta
Clinical management of osteogenesis imperfecta is multidisciplinary, encompassing substantial progress in physical rehabilitation and surgical procedures, management of hearing, dental and pulmonary abnormalities, as well as drugs, such as bisphosphonates and recombinant human growth hormone. Expand